[go: up one dir, main page]

RU2017113725A - Аналог бензофурана в качестве ингибитора ns4b - Google Patents

Аналог бензофурана в качестве ингибитора ns4b Download PDF

Info

Publication number
RU2017113725A
RU2017113725A RU2017113725A RU2017113725A RU2017113725A RU 2017113725 A RU2017113725 A RU 2017113725A RU 2017113725 A RU2017113725 A RU 2017113725A RU 2017113725 A RU2017113725 A RU 2017113725A RU 2017113725 A RU2017113725 A RU 2017113725A
Authority
RU
Russia
Prior art keywords
group
alkyl
compound
pharmaceutically acceptable
acceptable salt
Prior art date
Application number
RU2017113725A
Other languages
English (en)
Other versions
RU2672257C2 (ru
RU2017113725A3 (ru
Inventor
Ян ЧЖАН
Чжифэй ФУ
Цзяньфэй ВАН
Цзянь ЛИ
Шухуэй ЧЭНЬ
Юйцюань ВЭЙ
Лотин ЮЙ
Синь ТАО
Original Assignee
Чанчжоу Иньшэн Фармасьютикал Ко., Лтд.
Сычуань Юниверсити
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Чанчжоу Иньшэн Фармасьютикал Ко., Лтд., Сычуань Юниверсити filed Critical Чанчжоу Иньшэн Фармасьютикал Ко., Лтд.
Publication of RU2017113725A3 publication Critical patent/RU2017113725A3/ru
Publication of RU2017113725A publication Critical patent/RU2017113725A/ru
Application granted granted Critical
Publication of RU2672257C2 publication Critical patent/RU2672257C2/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/82—Benzo [b] furans; Hydrogenated benzo [b] furans with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C07D307/84—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D307/85—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Claims (36)

1. Соединение формулы (I),
Figure 00000001
(I),
или его фармацевтически приемлемая соль, где
компонент
Figure 00000002
может быть заменен на
Figure 00000003
или
Figure 00000004
;
ноль, один или два из T21-22 выбраны из N, при этом остальные из них выбраны из C(Rt);
каждый из D21-22, L1-2 независимо выбран из группы, состоящей из -[C(Rd1)(Rd2)]0-2-, -C(=O)-, -C(=O)N(Rd3)-, -N(Rd4)-, -C(=NRd5)-, -S(=O)2N(Rd6)-, -S(=O)N(Rd7)-, -O-, -S-, -C(=O)O-, -C(=S)-, -S(=O)-, -S(=O)2- и -N(Rd8)C(=O)N(Rd9)-;
m выбрано из группы, состоящей из 1, 2, 3 и 4;
R3 выбран из группы, состоящей из H, F, Cl, Br, I, CN, OH, SH, NH2, CHO, COOH, C(=O)NH2, S(=O)NH2 и S(=O)2NH2, или выбран из группы, состоящей из C1-10-алкила или гетероалкила, C3-10-циклогидрокарбила или гетероциклогидрокарбила и C1-10-алкила или гетероалкила, замещенного C3-10-циклогидрокарбилом или гетероциклогидрокарбилом, необязательно замещенных нолем, одним, двумя или тремя Rt;
каждый из R11-13, Rt, Rd1, Rd2 независимо выбран из группы, состоящей из H, F, Cl, Br, I, CN, OH, SH, NH2, CHO, COOH, C(=O)NH2, или выбран из группы, состоящей из C1-10-алкила или гетероалкила, C3-10-циклогидрокарбила или гетероциклогидрокарбила, C1-10-алкила или гетероалкила, замещенного C3-10-циклогидрокарбилом или гетероциклогидрокарбилом, необязательно замещенных нолем, одним, двумя или тремя R01;
R01 выбран из группы, состоящей из F, Cl, Br, I, CN, OH, SH, NH2 и R02;
R02 выбран из группы, состоящей из C1-10-алкила, C1-10-алкиламино, N,N-бис(C1-10-алкил)амино, C1-10-алкоксила, C1-10-алканоила, C1-10-алкоксикарбонила, C1-10-алкилсульфонила, C1-10-алкилсульфинила, C3-10-циклоалкила, C3-10-циклоалкиламино, C3-10-гетероциклоалкиламино, C3-10-циклоалкоксила, C3-10-циклоалканоила, C3-10-циклоалкоксикарбонила, C3-10-циклоалкилсульфонила и C3-10-циклоалкилсульфинила;
"гетеро" представляет собой гетероатом или гетероатомную группу, выбранную из группы, состоящей из -C(=O)N(Rd3)-, -N(Rd4)-, -C(=NRd5)-, -S(=O)2N(Rd6)-, -S(=O)N(Rd7)-, -O-, -S-, -C(=O)O-, -C(=O)-, -C(=S)-, -S(=O)-, -S(=O)2- и/или -N(Rd8)C(=O)N(Rd9)-;
каждый из Rd3-d9 независимо выбран из группы, состоящей из H, OH, NH2 и R02;
R02 необязательно замещен R001;
R001 выбран из группы, состоящей из F, Cl, Br, I, CN, OH, N(CH3)2, NH(CH3), NH2, CHO, COOH, C(=O)NH2, тригалогенметила, дигалогенметила, моногалогенметила, аминометила, гидроксиметила, метила, метиламино, формила, метоксикарбонила, метилсульфонила и метилсульфинила;
количество R01, R001, гетероатомов или гетероатомных групп независимо выбрано из группы, состоящей из 0, 1, 2 и 3;
необязательно существует другая соединяющая связь (CH2)1-3 между T21 и T22.
2. Соединение или его фармацевтически приемлемая соль по п. 1, где каждый из D21-22, L1-2 независимо выбран из группы, состоящей из (CH2)0-2, -C(=O)-, -C(=O)NH- и -C(=O)N(Me)-.
3. Соединение или его фармацевтически приемлемая соль по п. 1 или 2, где компонент
Figure 00000002
выбран из
Figure 00000005
, каждый из R101-103 независимо выбран из группы, состоящей из H, F, Cl, Br, I, CN, OH, SH, NH2, CHO, COOH, C(=O)NH2, или выбран из группы, состоящей из C1-10-алкила или гетероалкила, C3-10-циклогидрокарбила или гетероциклогидрокарбила и C1-10-алкила или гетероалкила, замещенного C3-10-циклогидрокарбилом или гетероциклогидрокарбилом, необязательно замещенных нолем, одним, двумя или тремя R01, при этом R01 определен в формуле изобретения.
4. Соединение или его фармацевтически приемлемая соль по п. 3, где каждый из R101-103 независимо выбран из группы, состоящей из F, Cl, Br, -CF3, -CHF2, CN, Me, этила, пропила, циклопропила и изопропила.
5. Соединение или его фармацевтически приемлемая соль по п. 3, где компонент
Figure 00000002
выбран из группы, состоящей из
Figure 00000006
,
Figure 00000007
,
Figure 00000008
,
Figure 00000009
,
Figure 00000010
,
Figure 00000011
,
Figure 00000012
,
Figure 00000013
и
Figure 00000014
;
или компонент
Figure 00000003
выбран из
Figure 00000015
;
или компонент
Figure 00000004
выбран из
Figure 00000016
.
6. Соединение или его фармацевтически приемлемая соль по п. 1, где компонент
Figure 00000017
выбран из группы, состоящей из
Figure 00000018
,
Figure 00000019
,
Figure 00000020
,
Figure 00000021
,
Figure 00000022
,
Figure 00000023
,
Figure 00000024
и
Figure 00000025
.
7. Соединение или его фармацевтически приемлемая соль по п. 1, где R3 выбран из группы, состоящей из
Figure 00000026
,
Figure 00000027
,
Figure 00000028
,
Figure 00000029
, -N(R33)(R34) и O(R35), или выбран из группы, состоящей из C1-3-алкила, циклопропила, фенила и пиридила, замещенных R001, где
каждый из T31-33 независимо выбран из группы, состоящей из N и C(Rt);
каждый из D31-35 независимо выбран из группы, состоящей из -[C(Rd1)(Rd2)]0-2-, -C(=O)-, -C(=O)N(Rd3)-, -N(Rd4)-, -C(=NRd5)-, -S(=O)2N(Rd6)-, -S(=O)N(Rd7)-, -O-, -S-, -C(=O)O-, -C(=S)-, -S(=O)- и -S(=O)2-;
каждый из R31-35 независимо выбран из группы, состоящей из H, F, Cl, Br, I, CN, OH, SH, NH2, CHO, COOH и C(=O)NH2, или выбран из группы, состоящей из C1-10-алкила или гетероалкила, необязательно замещенного R01, C3-10-циклогидрокарбила или гетероциклогидрокарбила, C1-10-алкила или гетероалкила, замещенного C3-10-циклогидрокарбилом и гетероциклогидрокарбилом;
определения Rt, Rd1-d7, R01 соответствуют таковым в п. 1;
необязательно существует другая соединяющая связь (CH2)1-3 между T31 и D31, D33 и D34, T33 и D35.
8. Соединение или его фармацевтически приемлемая соль по п. 1, где каждый из D31-35 независимо выбран из группы, состоящей из -C(=O)-, -O-, метилена, -N(CH3)-, -CH(OH)- и -CF2-; каждый из R31-34 независимо выбран из группы, состоящей из H, метила, этила, н-пропила и изопропила.
9. Соединение или его фармацевтически приемлемая соль по п. 1, где R3 выбран из группы, состоящей из
Figure 00000030
,
Figure 00000031
,
Figure 00000032
,
Figure 00000033
,
Figure 00000034
,
Figure 00000035
,
Figure 00000036
,
Figure 00000037
,
Figure 00000038
,
Figure 00000039
;
Figure 00000040
,
Figure 00000041
,
Figure 00000042
,
Figure 00000043
;
Figure 00000044
,
Figure 00000045
;
Figure 00000046
,
Figure 00000047
,
Figure 00000048
,
Figure 00000049
,
Figure 00000050
,
Figure 00000051
,
Figure 00000052
,
Figure 00000053
,
Figure 00000054
,
Figure 00000055
,
Figure 00000056
,
Figure 00000057
,
Figure 00000058
,
Figure 00000059
,
Figure 00000060
,
Figure 00000061
,
Figure 00000062
;
Figure 00000063
,
Figure 00000064
,
Figure 00000065
,
Figure 00000066
,
Figure 00000067
,
Figure 00000068
,
Figure 00000069
,
Figure 00000070
,
Figure 00000071
,
Figure 00000072
,
Figure 00000073
и
Figure 00000074
.
10. Соединение или его фармацевтически приемлемая соль по п. 1, выбранные из группы, состоящей из
Figure 00000075
,
Figure 00000076
,
Figure 00000077
,
Figure 00000078
,
Figure 00000079
,
Figure 00000080
,
Figure 00000081
,
Figure 00000082
,
Figure 00000083
,
Figure 00000084
,
Figure 00000085
,
Figure 00000086
,
Figure 00000087
,
Figure 00000088
,
Figure 00000089
,
Figure 00000090
,
Figure 00000091
,
Figure 00000092
,
Figure 00000093
,
Figure 00000094
,
Figure 00000095
,
Figure 00000096
,
Figure 00000097
,
Figure 00000098
,
Figure 00000099
,
Figure 00000100
,
Figure 00000101
,
Figure 00000102
,
Figure 00000103
,
Figure 00000104
,
Figure 00000105
,
Figure 00000106
,
Figure 00000107
,
Figure 00000108
,
Figure 00000109
,
Figure 00000110
,
Figure 00000111
,
Figure 00000112
,
Figure 00000113
,
Figure 00000114
,
Figure 00000115
,
Figure 00000116
,
Figure 00000117
,
Figure 00000118
,
Figure 00000119
,
Figure 00000120
,
Figure 00000121
,
Figure 00000122
,
Figure 00000123
,
Figure 00000124
,
Figure 00000125
,
Figure 00000126
,
Figure 00000127
,
Figure 00000128
,
Figure 00000129
,
Figure 00000130
,
Figure 00000131
,
Figure 00000132
,
Figure 00000133
,
Figure 00000134
,
Figure 00000135
,
Figure 00000136
,
Figure 00000137
,
Figure 00000138
,
Figure 00000139
,
Figure 00000140
,
Figure 00000141
и
Figure 00000142
.
RU2017113725A 2014-09-26 2015-09-23 Аналог бензофурана в качестве ингибитора ns4b RU2672257C2 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201410504810.0 2014-09-26
CN201410504810 2014-09-26
PCT/CN2015/090335 WO2016045587A1 (zh) 2014-09-26 2015-09-23 作为ns4b抑制剂的苯并呋喃类似物

Publications (3)

Publication Number Publication Date
RU2017113725A3 RU2017113725A3 (ru) 2018-10-26
RU2017113725A true RU2017113725A (ru) 2018-10-26
RU2672257C2 RU2672257C2 (ru) 2018-11-13

Family

ID=55580322

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2017113725A RU2672257C2 (ru) 2014-09-26 2015-09-23 Аналог бензофурана в качестве ингибитора ns4b

Country Status (8)

Country Link
US (1) US10100027B2 (ru)
EP (1) EP3199530A4 (ru)
JP (1) JP2017529401A (ru)
KR (1) KR101916701B1 (ru)
BR (1) BR112017006117A2 (ru)
RU (1) RU2672257C2 (ru)
TW (1) TW201613898A (ru)
WO (1) WO2016045587A1 (ru)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UY36060A (es) 2014-04-02 2015-10-30 Bayer Pharma AG Compuestos de azol sustituidos con amida
WO2022060764A1 (en) * 2020-09-18 2022-03-24 Merck Sharp & Dohme Corp. Modified benzofuran-carboxamides as glucosylceramide synthase inhibitors
WO2022106375A1 (en) * 2020-11-19 2022-05-27 F. Hoffmann-La Roche Ag Bicyclo[1.1.1]pentane compounds for the treatment and prophylaxis of hepatitis b virus infection
BR112023020806A2 (pt) 2021-04-09 2023-12-12 Immunic Ag Inibidores de dhodh deuterados
WO2025111414A1 (en) * 2023-11-21 2025-05-30 Katholieke Universiteit Leuven Trpm3-modulating benzofuran derivatives

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2757532A1 (de) 1977-12-23 1979-07-05 Hoechst Ag N,n'-disubstituiertes cyclisches diamin und verfahren zu dessen herstellung
US5912246A (en) 1995-02-15 1999-06-15 Pharmacia & Upjohn Company Imidazo 1,2-a!pyridines for the treatment of CNS and cardiac diseases
AU768720B2 (en) * 1999-04-01 2004-01-08 Pfizer Products Inc. Aminopyrimidines as sorbitol dehydrogenase inhibitors
EP1346987B1 (en) 2000-12-27 2006-05-03 Pola Chemical Industries, Inc. Benzofuran derivatives and pharmaceutical compositions containing the same
BR0315937A (pt) * 2002-11-01 2005-09-13 Viropharma Inc Composto, composição para a profilaxia ou tratamento de infecções virais, e, método para a profilaxia ou tratamento de infecções da hepatite c e doenças associadas com tais infecções em um hospedeiro vivo
TWI396686B (zh) * 2004-05-21 2013-05-21 Takeda Pharmaceutical 環狀醯胺衍生物、以及其製品和用法
DK1836179T3 (en) 2004-12-30 2015-05-26 Janssen Pharmaceutica Nv PIPERIDINE AND PIPERAZINE-1-CARBOXYLIC ACID AMIDE DERIVATIVES AND RELATED COMPOUNDS AS MODULATORS OF FAT ACID AMIDE HYDRALASE (FAAH) FOR THE TREATMENT OF ANCIENT, PAIN AND OTHER CONDITIONS
EP2023728A4 (en) 2006-05-26 2010-11-24 Janssen Pharmaceutica Nv OXAZOLYLPIPERIDINES AS MODULATORS OF FATTY ACID AMIDHYDROLASE
RU2009148304A (ru) 2007-05-25 2011-06-27 Янссен Фармацевтика Н.В. (Be) Модуляторы гидролазы амидов жирных кислот на основе гетероарилзамещенной мочевины
MX2010001650A (es) * 2007-08-10 2010-08-02 Glaxosmithkline Llc Entidades quimicas biciclicas que contienen nitrogeno para el tratamiento de infecciones virales.
CN101910145A (zh) 2008-02-14 2010-12-08 弗·哈夫曼-拉罗切有限公司 抗病毒的杂环化合物
US8198449B2 (en) 2008-09-11 2012-06-12 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
WO2010091411A1 (en) * 2009-02-09 2010-08-12 Glaxosmithkline Llc Piperidinyl cyclic amido antiviral agents
US20100204265A1 (en) * 2009-02-09 2010-08-12 Genelabs Technologies, Inc. Certain Nitrogen Containing Bicyclic Chemical Entities for Treating Viral Infections
JPWO2011001713A1 (ja) * 2009-06-29 2012-12-13 積水化学工業株式会社 めっき保護テープ
WO2011041713A2 (en) * 2009-10-02 2011-04-07 Glaxosmithkline Llc Piperazinyl antiviral agents
WO2011050284A1 (en) * 2009-10-23 2011-04-28 Glaxosmithkline Llc Pyrazolylpyridine antiviral agents
WO2012122716A1 (en) 2011-03-17 2012-09-20 Merck Sharp & Dohme Corp. Tetracyclic xanthene derivatives and methods of use thereof for treatment of viral diseases
CA2841095A1 (en) 2011-07-09 2013-01-17 Sunshine Lake Pharma Co., Ltd. Spiro compounds as hepatitis c virus inhibitors
WO2013095275A1 (en) 2011-12-20 2013-06-27 Medivir Ab Novel hepatitis c virus inhibitors
CN105732602B (zh) 2015-09-23 2017-04-19 常州寅盛药业有限公司 作为ns4b抑制剂的苯并呋喃类似物
TW201734011A (zh) * 2016-03-24 2017-10-01 常州寅盛藥業有限公司 苯並呋喃類似物製備方法及其中間體和晶型

Also Published As

Publication number Publication date
EP3199530A4 (en) 2017-10-04
JP2017529401A (ja) 2017-10-05
RU2672257C2 (ru) 2018-11-13
KR101916701B1 (ko) 2018-11-08
RU2017113725A3 (ru) 2018-10-26
TW201613898A (en) 2016-04-16
US20170240519A1 (en) 2017-08-24
BR112017006117A2 (pt) 2017-12-19
WO2016045587A1 (zh) 2016-03-31
EP3199530A1 (en) 2017-08-02
US10100027B2 (en) 2018-10-16
KR20170057429A (ko) 2017-05-24

Similar Documents

Publication Publication Date Title
RU2017113725A (ru) Аналог бензофурана в качестве ингибитора ns4b
ZA202006378B (en) N-heterocyclic five-membered ring-containing capsid protein assembly inhibitor, pharmaceutical composition thereof, and use thereof
RU2016135922A (ru) Терапевтические соединения и композиции
EA202092451A1 (ru) Соединения
DK4122954T3 (da) Novel GLP-1-analoger
EA201700504A1 (ru) 5-ароматическое алкинилзамещенное бензомидное соединение и способ его получения, фармацевтическая композиция и их применение
EA201690019A1 (ru) Производное аминотриазина и содержащая его фармацевтическая композиция
PE20142340A1 (es) Inhibidores de bromodominios
AR107864A1 (es) ÁCIDO 7a,11b-DIHIDROXI-6a-ETIL-5b-COLAN-24-OICO Y COMPOSICIONES FARMACÉUTICAS
MX388826B (es) Compuesto peptidico.
TW201613568A (en) Pharmaceutical composition comprising novel hydroxamic acid derivative or salt thereof
PE20170705A1 (es) Nuevos compuestos como inhibidores de ret (reorganizado durante la transfeccion)
JP2016522172A5 (ru)
JP2015024998A5 (ru)
TN2018000106A1 (en) Farnesoid x receptor modulators
MX392634B (es) Sal de un compuesto derivado de aminopiridina, una forma cristalina de esta y un proceso para prepararlo
EA201390969A1 (ru) Модуляторы глюкагонового рецептора
JP2013527242A5 (ru)
RU2021109549A (ru) ИНГИБИТОРЫ α-АМИНО-β-КАРБОКСИМУКОНАТ ε-СЕМИАЛЬДЕГИД-ДЕКАРБОКСИЛАЗЫ
JP2018501215A5 (ru)
RU2018146264A (ru) АЛЬФА- И БЕТА-НЕНАСЫЩЕННОЕ АМИДНОЕ СОЕДИНЕНИЕ - ПРОИЗВОДНОЕ БЕНЗОТРИАЗОЛА, ПРИМЕНЯЕМОЕ В КАЧЕСТВЕ ИНГИБИТОРА TGF-βRI
RU2016104844A (ru) Производные n-мочевино замещенных аминокислот как модуляторы формил-пептидного рецептора
RU2018146128A (ru) НОВЫЕ ИНГИБИТОРЫ β-ЛАКТАМАЗ
RU2017130595A (ru) Диазабензофторантреновые соединения
PE20201282A1 (es) Derivados de piridinona y su uso como inhibidores selectivos de alk-2

Legal Events

Date Code Title Description
MM4A The patent is invalid due to non-payment of fees

Effective date: 20200924